Comparative Pharmacology
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus SYNTHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus SYNTHROID.
LIOTHYRONINE SODIUM vs SYNTHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
Synthetic levothyroxine is a replacement for endogenous thyroid hormone. It binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
Initial adult dose 1.6 mcg/kg orally once daily, adjusted by 12.5-25 mcg increments every 6-8 weeks based on TSH levels. Maintenance dose typically 100-125 mcg/day.
None Documented
None Documented
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
Levothyroxine (T4) terminal elimination half-life: 6-7 days in euthyroid patients; shortened to 3-4 days in hyperthyroidism and prolonged to 9-10 days in hypothyroidism; clinical context: supports once-daily dosing with steady-state reached after 6-8 weeks.
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Renal: ~20-40% of T4 and T3 metabolites excreted in urine as glucuronide and sulfate conjugates; fecal: ~40-60% as unchanged drug and conjugates via biliary elimination; minor amounts in bile and feces as deiodinated products.
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone